Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival

Pauline Rochefort , Sylvie Chabaud (1) , Jean-Yves Pierga (2) , Olivier Trédan , Etienne Brain (3) , François-Clément Bidard (2) , Camille Schiffler , Helena Polena (4) , Abir Khalil-Mgharbel , Isabelle Vilgrain (4) , Thomas Bachelot (5)

1 Centre Léon Bérard [Lyon]
2 Service d'Oncologie Médicale
3 ICSC - Institut Curie - Saint Cloud
4 Laboratoire de développement et vieillissement de l'endothélium
5 Oncogénèse et progression tumorale

Patients with metastatic breast cancer (MBC) represent a heterogeneous group, with large differences in outcomes from individual patients. VE-cadherin, an endothelial-specific cadherin, was shown to promote tumour proliferation and angiogenesis. Soluble VE-cadherin has been recently associated to breast cancer progression. This study was designed to investigate the prognosis significance of soluble VE-cadherin in hormone-refractory MBC.

Domaines: Médicaments; Cancer

Pauline Rochefort, Sylvie Chabaud, Jean-Yves Pierga, Olivier Trédan, Etienne Brain, et al.. Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival. British Journal of Cancer, 2017, 116 (3), pp.356-361. ⟨10.1038/bjc.2016.427⟩. ⟨hal-02005081⟩